A detailed history of Bank Of America Corp transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 405,601 shares of SUPN stock, worth $12.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
405,601
Previous 360,599 12.48%
Holding current value
$12.9 Million
Previous $12.3 Million 11.8%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.99 - $33.85 $1.17 Million - $1.52 Million
45,002 Added 12.48%
405,601 $10.8 Million
Q1 2024

May 15, 2024

SELL
$27.11 - $35.17 $110,581 - $143,458
-4,079 Reduced 1.12%
360,599 $12.3 Million
Q4 2023

Feb 14, 2024

BUY
$22.72 - $29.68 $1.41 Million - $1.84 Million
62,001 Added 20.48%
364,678 $10.6 Million
Q2 2023

Aug 14, 2023

SELL
$29.91 - $38.73 $1.06 Million - $1.37 Million
-35,491 Reduced 10.5%
302,677 $9.1 Million
Q1 2023

May 12, 2023

BUY
$34.93 - $42.03 $46,910 - $56,446
1,343 Added 0.4%
338,168 $12.3 Million
Q4 2022

Feb 10, 2023

BUY
$31.09 - $37.88 $53,847 - $65,608
1,732 Added 0.52%
336,825 $12 Million
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $349,740 - $430,160
12,148 Added 3.76%
335,093 $11.3 Million
Q2 2022

Aug 12, 2022

SELL
$25.33 - $34.25 $4.59 Million - $6.21 Million
-181,228 Reduced 35.95%
322,945 $9.34 Million
Q1 2022

May 16, 2022

SELL
$28.51 - $32.9 $876,568 - $1.01 Million
-30,746 Reduced 5.75%
504,173 $16.3 Million
Q4 2021

Feb 08, 2022

BUY
$26.37 - $34.22 $1.39 Million - $1.8 Million
52,661 Added 10.92%
534,919 $15.6 Million
Q3 2021

Nov 15, 2021

SELL
$23.54 - $31.39 $2.35 Million - $3.13 Million
-99,793 Reduced 17.15%
482,258 $12.9 Million
Q2 2021

Sep 13, 2021

BUY
$26.72 - $33.19 $15.6 Million - $19.3 Million
582,051 New
582,051 $17.9 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.7B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.